Name: Cancer Immunotherapy in Urology, an Issue of Urologic Clinics (Volume 47-4) (The Clinics: Surgery, Volume 47-4)
Price: 348.78 PEN
Availability: InStock
Author: Nair/Tewari
ISBN: 9780323754989

portada Cancer Immunotherapy in Urology, an Issue of Urologic Clinics (Volume 47-4) (The Clinics: Surgery, Volume 47-4)

Cancer Immunotherapy in Urology, an Issue of Urologic Clinics (Volume 47-4) (The Clinics: Surgery, Volume 47-4)

Formato

Libro Físico

Editorial

Elsevier Ltd

Autor

Nair/Tewari

Encuadernación

Tapa Dura

ISBN13

9780323754989

Cancer Immunotherapy in Urology, an Issue of Urologic Clinics (Volume 47-4) (The Clinics: Surgery, Volume 47-4)

Nair/Tewari (Autor) · Elsevier Ltd · Tapa Dura

Libro Nuevo Importado

Envío: 18 a 23 días háb.

S/ 775,08S/ 348,78

-55%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

S/ 348,78

Llega entre el 31 Ago y el 08 Sep a CERCADO DE LIMA, Lima. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Cancer Immunotherapy in Urology, an Issue of Urologic Clinics (Volume 47-4) (The Clinics: Surgery, Volume 47-4)"

The Guest Editors of this issue of Urologic Clinics of North America have put together a comprehensive collection of articles that provides the current knowledge on urologic cancer immunotherapy. Expert authors have contributed clinical review articles on the following topics: Era of personalized vaccines for GU cancers; TCR and dendritic vaccine platforms for GU cancers; Neo-adjuvant platforms for GU cancer immunotherapy; Immune-editing in Cancer: Role of tumor microenvironment and immune-suppressive pathways in localized and aggressive disease; Clinical integration of neo-adjuvant platforms for prostate cancer immunotherapy; Immunotherapy for muscle and non-muscle invasive bladder cancer: BCG and beyond; Immunotherapy for metastatic bladder cancer; Immunotherapy options for metastatic castrate-resistant prostate cancer; Role of tissue infiltrating lymphocytes: Understanding TCR; Therapeutic platforms for IPSC-derived CAR-T; Immune-suppression in prostate cancer: Underlying causes and influence on response to immunotherapy; and Racial disparity in response to immunotherapy. Urologists will come away with the most current information they need to improve outcomes in the urologic cancer patient.